Phaseline

Companies › Fusion Pharmaceuticals

Fusion Pharmaceuticals: clinical trials, targets and expected readouts

1 active drug program in 3 registered trials: 3 Phase 2; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
FPI-2265
Ac-225-labeled PSMA-targeting small molecule (targeted alpha therapy)
PSMA, FOLH1Phase 2Metastatic Castration Resistant Prostate Cancer; Metastatic Castration-resistant Prostate CancerDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05219500FPI-2265Phase 2Metastatic Castration Resistant Prostate CancerOncologyMay 2025
NCT06402331FPI-2265Phase 2Metastatic Castration-resistant Prostate CancerOncologyDec 2026
NCT06909825FPI-2265Phase 2Metastatic Castration-resistant Prostate CancerOncologyMay 2027

Targets

PSMA (1) FOLH1 (1)

Companies with the same targets

Clarity Pharmaceuticals Novartis C Ray Therapeutics Curium US Johnson & Johnson (Janssen) Telix Pharmaceuticals (Innovations) Nova Therapeutics Eli Lilly Lantheus Medical Imaging Sinotau Pharmaceutical Group

Companies built like this

Clarity Pharmaceuticals Curium US ABX advanced biochemical compounds POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company Shanghai Guangsheng Biopharmaceutical

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.